Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini(Cleveland Clinic), Thomas Powles(University College London), Michael B. Atkins(Georgetown Lombardi Comprehensive Cancer Center), Bernard Escudier(Institut Gustave Roussy), David F. McDermott(Beth Israel Deaconess Medical Center), Cristina Suárez(Universitat Autònoma de Barcelona), Sergio Bracarda(Azienda Ospedaliera S.Maria), Walter M. Stadler(University of Chicago), Frede Donskov(Aarhus University Hospital), Jae‐Lyun Lee(Asan Medical Center), Robert D. Hawkins(The Christie NHS Foundation Trust), Alain Ravaud(Hôpital Saint-André), B. Yа. Alekseev(P.A. Hertzen Moscow Oncology Research Institute), Michael Staehler(LMU Klinikum), Motohide Uemura(Osaka University), Ugo De Giorgi(Istituti di Ricovero e Cura a Carattere Scientifico), Begoña Mellado, Camillo Porta(Istituti di Ricovero e Cura a Carattere Scientifico), Bohuslav Melichar(University Hospital Olomouc), Howard Gurney(Macquarie University), Jens Bedke(University of Tübingen), Toni K. Choueiri(Dana-Farber Cancer Institute), Francis Parnis, Tarik Khaznadar(Roche (Switzerland)), Alpa Thobhani(Roche (United Kingdom)), Shi Li, Elisabeth Piault‐Louis, Gretchen Frantz, Mahrukh Huseni, Christina Schiff, Marjorie C. Green, Robert J. Motzer(Memorial Sloan Kettering Cancer Center)
Cited by 1,006
Abstract
Related Papers
No related papers found
Powered by citation graph analysis